PRE-APPROVAL ACCESS (PAA) Single Patient Request (SPR) TREATMENT GUIDELINES for Teclistamab (JNJ-64007957) for Treating Physician Use
Latest Information Update: 18 Aug 2022
At a glance
- Drugs Teclistamab (Primary)
- Indications Multiple myeloma
- Focus Expanded access; Therapeutic Use
- Sponsors Janssen Research & Development
- 20 Jun 2022 Status changed from recruiting to completed.
- 11 Jan 2022 Status changed from suspended to recruiting.
- 23 Dec 2021 New trial record